EP4332221 - THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 22.03.2024 Database last updated on 03.09.2024 | |
Former | The application has been published Status updated on 02.02.2024 | Most recent event Tooltip | 22.03.2024 | Withdrawal of application | published on 24.04.2024 [2024/17] | Applicant(s) | For all designated states Roche Innovation Center Copenhagen A/S Fremtidsvej 3 2970 Hørsholm / DK | For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [2024/10] | Representative(s) | Rodriguez Novoa, Lorena F. Hoffmann-La Roche AG Patent Department Grenzacherstrasse 124 4070 Basel / CH | [2024/10] | Application number, filing date | 22192656.1 | 29.08.2022 | [2024/10] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4332221 | Date: | 06.03.2024 | Language: | EN | [2024/10] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 22.05.2023 | Classification | IPC: | C12N15/113, C12N15/11 | [2024/10] | CPC: |
C12N15/111 (EP);
C12N15/113 (EP);
C12N2310/11 (EP);
C12N2310/315 (EP);
C12N2310/319 (EP);
C12N2310/32 (EP);
| C-Set: |
C12N2310/321, C12N2310/3525 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/10] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | THREOSE-NUKLEINSÄURE-ANTISENSE-OLIGONUKLEOTIDE UND VERFAHREN DAFÜR | [2024/10] | English: | THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF | [2024/10] | French: | OLIGONUCLÉOTIDES ANTISENS D'ACIDE NUCLÉIQUE À THRÉOSE ET PROCÉDÉS ASSOCIÉS | [2024/10] | Examination procedure | 20.12.2022 | Loss of particular rights, legal effect: Claims | 25.01.2023 | Despatch of communication of loss of particular rights: Claims {1} | 15.03.2024 | Despatch of communication that the application is refused, reason: Examination on filing A.90(5) {1} | 19.03.2024 | Application withdrawn by applicant [2024/17] |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I] - WANG FEI ET AL., "Synthetic alpha-L-Threose nucleic acids targeting BcL-2 show gene silencing and in vivo antitumor activity for cancer therapy", APPLIED MATERIALS & INTERFACES, US, (20190926), vol. 11, no. 42, doi:10.1021/acsami.9b14324, ISSN 1944-8244, pages 38510 - 38518, XP093031784 [I] 1-15 * the whole document * DOI: http://dx.doi.org/10.1021/acsami.9b14324 | [I] - Wang Fei ET AL., "Supporting Information", (20190926), URL: https://pubs.acs.org/doi/10.1021/acsami.9b14324#, (20230510), XP093045923 [I] 1-15 * the whole document * | [I] - LIU LING SUM ET AL., "alpha-L-Threose nucleic acids as biocompatible antisense oligonucleotides for suppressing gene expression in living cells", APPLIED MATERIALS & INTERFACES, US, (20180223), vol. 10, no. 11, doi:10.1021/acsami.8b01180, ISSN 1944-8244, pages 9736 - 9743, XP093031816 [I] 1-15 * the whole document * DOI: http://dx.doi.org/10.1021/acsami.8b01180 | [I] - Ling Sum ET AL., "Supporting Information", (20180223), URL: https://pubs.acs.org/doi/10.1021/acsami.8b01180, (20230510), XP093045921 [I] 1-15 * the whole document * | [A] - ROBERTS THOMAS C. ET AL., "Advances in oligonucleotide drug delivery", NATURE REVIEWS DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 19, no. 10, doi:10.1038/S41573-020-0075-7, ISSN 1474-1776, (20200811), pages 673 - 694, (20200811), XP037256878 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1038/s41573-020-0075-7 | by applicant | WO9839352 | WO9914226 | WO0047599 | WO0066604 | WO0123613 | WO2004046160 | WO2007031091 | WO2007090071 | WO2007134181 | WO2008049085 | WO2008150729 | WO2008154401 | WO2009006478 | WO2009067647 | WO2010036698 | WO2010077578 | WO2011017521 | WO2011156202 | WO2012078536 | WO2012109395 | WO2012118911 | WO2013022984 | WO2013154798 | WO2013179292 | WO2014076195 | WO2015113922 | - VESTER et al., Bioorg. Med. Chem. Lett., (20080000), vol. 18, pages 2296 - 2300 | - ECKSTEIN, Antisense and Nucleic Acid Drug Development, (20090000), vol. 10, pages 117 - 121 | - CROOKE et al., Nucleic Acids Research, (20200000), vol. 48, no. 10, pages 5235 - 5253 | - LIU et al., ACS Appl. Mater. Interfaces, (20180000), vol. 10, pages 9736 - 9743 | - HIRAO et al., Accounts of Chemical Research, (20120000), vol. 45, page 2055 | - FREIERALTMANN, Nucl. Acid Res., (19970000), vol. 25, pages 4429 - 4443 | - UHLMANN, Curr. Opinion in Drug Development, (20000000), vol. 3, no. 2, pages 293 - 213 | - DELEAVEYDAMHA, Chemistry and Biology, (20120000), vol. 19, page 937 | - MORITA et al., Bioorganic & Med. Chem. Lett., (20020000), vol. 12, pages 73 - 76 | - SETH et al., J. Org. Chem., (20100000), vol. 75, no. 5, pages 1569 - 81 | - MITSUOKA et al., Nucleic Acids Research, (20090000), vol. 37, no. 4, pages 1225 - 1238 | - WANSETH, J. Medical Chemistry, (20160000), vol. 59, pages 9645 - 9667 | - MERGNYLACROIX, Oligonucleotides, (20030000), vol. 13, pages 515 - 537 | - HANSEN et al., Chem. Comm., (19650000), vol. 36-38 | - SANTALUCIA, Proc Natl Acad Sci USA., vol. 95, pages 1460 - 1465 | - SUGIMOTO et al., Biochemistry, (19950000), vol. 34, pages 11211 - 11216 | - MCTIGUE et al., Biochemistry, (20040000), vol. 43, pages 5388 - 5405 | - MANGOS et al., J. AM. CHEM. SOC., (20030000), vol. 125, pages 654 - 661 | - FLUITER et al., Mol. Biosyst., (20090000), vol. 10, page 1039 | - RUKOV et al., Nucl. Acids Res. Vol., (20150000), vol. 43, pages 8476 - 8487 | - CARUTHERS et al., Methods in Enzymology, (19870000), vol. 154, pages 287 - 313 | - BASTIN, Organic Process Research & Development, (20000000), vol. 4, pages 427 - 435 | - ANSEL, Pharmaceutical Dosage Forms and Drug Delivery Systems, (19950000), pages 196,1456 - 1457 | - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533 | - ZHANG et al., Chem. Inf. Model., (20120000), vol. 52, no. 10, pages 2796 - 2806 | - ZHANGCHAPUT, Current Protocols in Nucleic Acid Chemistry | WO2009EP50349 |